HD-OPM Archive
Topics › Inflammation & CRP

Calprotectin predicts ASCVD independent of traditional risk factors (JAMA Cardiology)

Louis Nervegna · Aug 04, 2025 · ♥ 4 reactions · 0 comments · original Facebook post
Inflammation & CRPRisk assessment & lab testsPlaque, CAC & CT angiography
AI summary & key facts

Louis shares a JAMA Cardiology finding that calprotectin may be a mechanistically informed biomarker of atherosclerotic disease. It rises with arterial inflammation and adds risk information beyond standard factors.

Calprotectin is a marker of neutrophil activation.

It rises in association with arterial inflammation.

It appears to predict risk for CVD independent of traditional risk factors, and there are mechanistic reasons for why.

Quoted:

“There is growing evidence of the immune system’s pivotal role in the progression of atherosclerotic cardiovascular disease (ASCVD). Triggered by endothelial damage and lipid deposition, innate and adaptive immune cells become activated, leading to vascular inflammation and contributing to atherosclerotic plaque formation and progression [1]. This understanding has intensified research into links between the immune system and ASCVD development [1]. Innate immune cells, such as neutrophils and macrophages, are the first responders to tissue damage and are crucial in initiating inflammation and tissue repair [2,3]. Heightened neutrophil production appears to be a key factor in the development and progression of atherosclerotic plaques.”

“Findings: High calprotectin levels were associated with an increased risk of ASCVD events over 8 years, even after adjusting for traditional cardiovascular risk factors as well as high-sensitivity C-reactive protein, N-terminal pro–brain natriuretic peptide, and high-sensitivity cardiac troponin T. Mechanistically, calprotectin impaired coronary endothelial integrity, reduced nitric oxide production, and promoted endothelial to mesenchymal transition.

Meaning: Calprotectin has the potential to be a mechanistically informed biomarker for ASCVD, independent of traditional and contemporary cardiovascular risk factors and biomarkers.”

#calprotectinHD #neutrophilsHD #inflammationHD #plaqueHD #endotheliumHD #nitricoxideHD

Research cited

Calprotectin may serve as a mechanistically informed biomarker for atherosclerotic cardiovascular disease, independent of traditional and contemporary cardiovascular risk factors and biomarkers. Epidemiological and Translational Study of Calprotectin and Atherosclerotic… (JAMA Cardiol, 2025)

No photo description available.
← newer: CARDIAL-MS proposed as one multisystem metabolic disease (heolder: Swapping 1 tbsp butter daily for plant oil linked to 17% low →